Cargando…

Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors

The incidence of severe immune-related adverse events (irAEs) in cancer subjects receiving immune checkpoint inhibitors (ICIs) following COVID-19 vaccination and the relationship between the incidence of severe irAE and the interval between COVID-19 vaccination and ICI dose have not been established...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gilbert, Danielle, Hu, Junxiao, Medina, Theresa, Kessler, Elizabeth R., Lam, Elaine T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Coronavirus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294768/ https://www.ncbi.nlm.nih.gov/pubmed/37157982 http://dx.doi.org/10.1080/21645515.2023.2207438

Ejemplares similares

Willingness of college students to receive COVID-19 heterologous vaccination: Comment
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Willingness of college students to receive COVID-19 heterologous vaccination in Taizhou, China
por: Shao, Hui, et al.
Publicado: (2023)

Bivalent second booster dose of the COVID-19 vaccine: Eligible populations’ reasons for receiving in Italy
por: Della Polla, Giorgia, et al.
Publicado: (2023)

The association between adverse events of COVID-19 vaccination and anxiety and willingness to receive a booster dose
por: Chen, Liling, et al.
Publicado: (2023)

Intention to receive COVID-19 vaccine and its health belief model (HBM)-based predictors: Comment
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Comparison of self-reported symptoms in COVID-19 patients who had or had not previously received COVID-19 mRNA vaccination
por: Hara, Megumi, et al.
Publicado: (2023)

Intention to receive COVID-19 vaccine and its health belief model (HBM)-based predictors: A systematic review and meta-analysis
por: Yenew, Chalachew, et al.
Publicado: (2023)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Chatting with ChatGPT to learn about safety of COVID-19 vaccines – A perspective
por: Salas, Antonio, et al.
Publicado: (2023)

Confidence in COVID-19 vaccine effectiveness and safety and its effect on vaccine uptake in Tanzania: A community-based cross-sectional study
por: Mtei, Monica, et al.
Publicado: (2023)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Factors influencing attitudes toward vaccine safety and vaccine effectiveness amongst UK healthcare professionals prior to and at the time of COVID-19 vaccine rollout: Insights from the CoPE-HCP cohort study
por: Collett, George, et al.
Publicado: (2023)

Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques
por: Xu, Fang, et al.
Publicado: (2022)

Booster vaccination is required to elicit and maintain COVID-19 vaccine-induced immunity in SIV-infected macaques
por: Li, Pingchao, et al.
Publicado: (2023)

Safety evaluation of COVID-19 vaccination during early pregnancy: A single-center prospective cohort study of Chinese pregnant women
por: Lu, Ling, et al.
Publicado: (2023)

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
por: Costa Clemens, Sue Ann, et al.
Publicado: (2023)

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial
por: Thuluva, Subhash, et al.
Publicado: (2023)

Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults
por: Yassini, Patrick, et al.
Publicado: (2023)

Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Author’s reply to correspondence
por: Ripabelli, Giancarlo, et al.
Publicado: (2023)

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan
por: Terada-Hirashima, Junko, et al.
Publicado: (2023)

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants
por: Lam, Joy-Yan, et al.
Publicado: (2022)

Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV
por: Wang, Qian, et al.
Publicado: (2022)

The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development
por: Yu, Haiyun, et al.
Publicado: (2023)

Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents
por: Lopez, Pio, et al.
Publicado: (2023)

Attitudes and behavior of medical students toward receiving the COVID-19 vaccine
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Trajectory of COVID-19 vaccine hesitancy post-vaccination and public’s intention to take booster vaccines: A cross-sectional analysis
por: Salman, Muhammad, et al.
Publicado: (2023)

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
por: Wang, Xinling, et al.
Publicado: (2023)

Correlates of uptake of COVID-19 vaccines and motivation to vaccinate among Malawian adults
por: Whitehead, Hannah S., et al.
Publicado: (2023)

A case–case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variants
por: Wu, Dan, et al.
Publicado: (2022)

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
por: Fortunato, Francesca, et al.
Publicado: (2023)

A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants
por: Pérez-Vargas, Jimena, et al.
Publicado: (2023)

Medium-term outcomes of myocarditis and pericarditis following BNT162b2 vaccination among adolescents in Hong Kong
por: Chua, Gilbert T., et al.
Publicado: (2022)

COVID-19 mass vaccination – an illustration of the impact of syringe choice on the effectiveness of mass vaccination campaigns
por: Mazet, Roseline, et al.
Publicado: (2022)

Tracking trends in COVID-19 vaccines based on 47 different vaccines: A bibliometric review
por: Tao, Zhongbin, et al.
Publicado: (2023)

COVID-19 vaccine hesitancy: misinformation and perceptions of vaccine safety
por: Kricorian, Katherine, et al.
Publicado: (2021)

Single cell characteristics of patients with vaccine-related adverse reactions following inactivated COVID-19 vaccination
por: Jiang, Manling, et al.
Publicado: (2023)

Why is it necessary to improve COVID-19 vaccination coverage in older people? How to improve the vaccination coverage?
por: Zhu, Ke-Wei
Publicado: (2023)

COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia
por: Yang, Su Lan, et al.
Publicado: (2022)

Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses
por: He, Qian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ve77n44pjnkvefdl75s9d0ausv